Skip to content

Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy

Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07313384
Acronym
DINE-GLP1
Enrollment
50
Registered
2025-12-31
Start date
2026-02-11
Completion date
2026-12-01
Last updated
2026-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity (Disorder), Obesity Type 2 Diabetes Mellitus

Keywords

GLP-1 Therapy, Nutrition Support, Obesity, Weight loss therapy

Brief summary

The DINE-GLP1 study aims to understand how people on GLP-1 therapy change their eating habits and what kind of dietary support they need. As more people use GLP-1 medications, there's not much guidance on what they should eat, mostly just focusing on managing symptoms and cutting calories. Since these medications reduce food intake, it's important to ensure the diet is nutritious even with fewer calories to help with long-term weight control and health. Most research has looked at how the body responds to the medication and whether patients take it as prescribed, but not much is known about what patients actually experience, what they think they need, or how they could use additional support. Understanding patients' views can help create better lasting solutions. Note that this study does not provide free GLP-1 medication.

Interventions

Exposure to GLP-1 Therapy for obesity or T2DM management.

Sponsors

University of South Carolina
Lead SponsorOTHER
Prisma Health-Upstate
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults aged 18 and older * Recently has been prescribed GLP-1 therapy for the treatment of obesity or T2DM but have not yet initiated the medication * Has regular access to a smartphone and internet to complete short surveys and food recalls online * Willing to sign informed consent.

Exclusion criteria

* Already began the GLP-1 medication * Have medical concerns making participation unsafe

Design outcomes

Primary

MeasureTime frameDescription
Change in Healthy Eating IndexBaseline and 12-weeksThe Healthy Eating Index (HEI) is a scoring metric developed by the U.S. Department of Agriculture (USDA) and the NCI to assess how well a person's diet conforms to the Dietary Guidelines for Americans. It evaluates the consumption of 13 dietary components, including both adequacy (foods to increase) and moderation (foods to decrease). The scores range from 0 to 100. An ideal overall HEI score of 100 reflects that the set of foods aligns with key dietary recommendations and dietary patterns published in the Dietary Guidelines.

Secondary

MeasureTime frameDescription
Change in Body WeightBaseline and 12 weeksChange from Baseline in Body Weight at 12-weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 24, 2026